Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1970 1
1971 10
1972 8
1973 71
1974 94
1975 124
1976 90
1977 118
1978 204
1979 214
1980 199
1981 213
1982 191
1983 246
1984 306
1985 291
1986 304
1987 302
1988 265
1989 278
1990 251
1991 268
1992 239
1993 232
1994 194
1995 212
1996 159
1997 193
1998 161
1999 173
2000 172
2001 170
2002 186
2003 209
2004 202
2005 207
2006 216
2007 246
2008 230
2009 210
2010 253
2011 283
2012 233
2013 264
2014 254
2015 273
2016 256
2017 259
2018 217
2019 101
2020 2
Text availability
Article attribute
Article type
Publication date

Search Results

9,658 results
Results by year
Filters applied: . Clear all
Page 1
Circulating and intrahepatic antiviral B cells are defective in hepatitis B.
Burton AR, et al. J Clin Invest 2018 - Clinical Trial. PMID 30091725 Free PMC article.
B cells are increasingly recognized as playing an important role in the ongoing control of hepatitis B virus (HBV). The development of antibodies against the viral surface antigen (HBV surface antigen [HBsAgs]) constitutes the hallmark of resolution of acute infection and is a therapeutic goal for functional cure of chronic HBV (CHB). ...However, purified, differentiated HBsAg-specific B cells from patients with CHB had defective antibody production, consistent with undetectable anti-HBs antibodies in vivo. ...
B cells are increasingly recognized as playing an important role in the ongoing control of hepatitis B virus (HBV). The
Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults.
Jackson S, et al. Vaccine 2018 - Clinical Trial. PMID 29289383 Free article.
BACKGROUND: Hepatitis B virus infection remains an important public health problem in the United States. Currently approved alum-adjuvanted vaccines require three doses and have reduced immunogenicity in adults, particularly in those who have diabetes mellitus, or are older, male, obese, or who smoke. ...With fewer doses in a shorter time, and greater immunogenicity, HBsAg-1018 has the potential to significantly improve protection against hepatitis B in adults at risk for hepatitis B infection. ...
BACKGROUND: Hepatitis B virus infection remains an important public health problem in the United States. Currently approved al …
Viral envelope-specific antibodies in chronic hepatitis B virus infection.
Corti D, et al. Curr Opin Virol 2018 - Review. PMID 29738926
While the cellular immune response associated with acute and chronic HBV infection has been thoroughly studied, the B cell response in chronic hepatitis B and the role of antibodies raised against the HBV envelope antigens in controlling and prevention of infection requires further investigation. The detection of anti-HBs antibodies is considered as one of the biomarkers for functional cure of chronic hepatitis B virus infection, as well as for protective immunity. ...
While the cellular immune response associated with acute and chronic HBV infection has been thoroughly studied, the B cell response i …
Status and progress of hepatitis B control through vaccination in the South-East Asia Region, 1992-2015.
Childs L, et al. Vaccine 2018 - Review. PMID 29174317 Free PMC article.
Chronic hepatitis B virus (HBV) infection is largely preventable with a birth dose of hepatitis B vaccine (HepB-BD) followed by two to three additional doses. We reviewed the progress towards hepatitis B control through vaccination in SEAR during 1992-2015. We summarized hepatitis B vaccination data and reviewed the literature to determine the prevalence of chronic HBV infection pre- and post-vaccine introduction. ...
Chronic hepatitis B virus (HBV) infection is largely preventable with a birth dose of hepatitis B vaccine (HepB- …
Hepatitis B status in hemodialysis patients.
Guimarães MNC, et al. Arq Gastroenterol 2017. PMID 28724049 Free article.
BACKGROUND: Patients on chronic dialysis present a high prevalence of hepatitis B virus infection. Despite infection-control practices, surveillance of serological markers, and hepatitis B vaccination, there are still outbreaks of the disease in dialysis centers. OBJECTIVE: This study aims to assess the serologic and vaccination status for hepatitis B in hemodialysis patients. METHODS: This cross-sectional study assessed serologic markers and hepatitis B vaccination status of chronic kidney disease patients on regular dialysis program in São Carlos, SP, Brazil. ...
BACKGROUND: Patients on chronic dialysis present a high prevalence of hepatitis B virus infection. Despite infection-control p …
No. 342-Hepatitis B and Pregnancy.
Castillo E, et al. J Obstet Gynaecol Can 2017 - Review. PMID 28284515
OBJECTIVE: To review the epidemiology, natural history, evaluation, and treatment of hepatitis B virus (HBV) infection during pregnancy. This will aid obstetric care providers in counseling their patients regarding perinatal risks and management options available to pregnant women with hepatitis B. ...
OBJECTIVE: To review the epidemiology, natural history, evaluation, and treatment of hepatitis B virus (HBV) infection during …
Isolated anti-HBc: The Relevance of Hepatitis B Core Antibody-A Review of New Issues.
Wu T, et al. Am J Gastroenterol 2017 - Review. PMID 29087395
Hepatitis B core antibody (anti-HBc) is considered the most sensitive serological marker for history of hepatitis B virus (HBV) infection. In a subset of anti-HBc carriers, anti-HBc is present in the absence of hepatitis B surface antigen and hepatitis B surface antibody-a serological pattern known as "isolated anti-HBc" (IAHBc). ...
Hepatitis B core antibody (anti-HBc) is considered the most sensitive serological marker for history of hepatitis B
Hepatitis B Vaccination in Patients Receiving Oral Antiviral Therapy Without Hepatitis B Immunoglobulin After Liver Transplant.
Wong TCL, et al. Transplant Proc 2018. PMID 30577255
Our study aimed to determine if a double-dose pre-S containing hepatitis B virus (HBV) vaccination (Sci-B-Vac) could elicit an adequate and sustainable immune response in HBV patients who developed spontaneous hepatitis B surface antibody (anti-HBs) response after liver transplant. PATIENTS AND METHODS: All patients who received transplants for HBV-related disease for >1 year with normal graft function and hepatitis B surface antigen seronegativity were evaluated. ...
Our study aimed to determine if a double-dose pre-S containing hepatitis B virus (HBV) vaccination (Sci-B-Vac) could el …
Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: A meta-analysis.
Paul S, et al. Hepatology 2017 - Review. PMID 28128861 Free PMC article.
Patients with resolved hepatitis B virus (HBV) infection who are treated for hematological malignancies remain at risk for HBV reactivation. ...In 20 studies involving 1,672 patients not receiving antiviral prophylaxis, the reactivation risk was 14% (95% confidence interval [CI] 9.4%-19%) in 388 patients who had antibodies to hepatitis B core antigen only versus 5.0% (95% CI 3.0%-7.0%) in 1,284 patients who also had anti-HBs. ...
Patients with resolved hepatitis B virus (HBV) infection who are treated for hematological malignancies remain at risk for HBV …
9,658 results
Jump to page
Feedback